Advanced Enzyme Technologies Limited — PPTs, 02-08-2025: Investor Presentation

**Financial Highlights:**

Quarterly revenue rose 20% year-over-year to ₹185.9 Cr; net profit increased 16% to ₹40.4 Cr. EBITDA margin was 30%, PAT margin 22%. Human and Animal Nutrition segments drove growth, with India revenue up 32%.

**Strategic Initiatives & Growth Drivers:**

AETL plans continuous R&D for new enzymes/probiotics and expanding genetic engineering for high-return applications. Geographic expansion via partnerships and strategic acquisitions are also key growth pillars. Future focus areas include Animal Nutrition sales, new human/animal probiotics, bio-catalysis for APIs, and global baking solutions.

**Business Developments:**

This quarter's performance was primarily driven by Human Nutrition (66% of revenue) and a strong surge in Animal Nutrition.

**Market Position & Competitive Advantage:**

AETL is a leading, cost-competitive global enzyme/probiotic manufacturer. It boasts strong R&D, an integrated value chain, serves diverse customers globally, and benefits from high industry entry barriers.

**Investor Implications:**

Strong quarterly results and clear growth strategies across diversified, high-potential segments suggest positive growth potential. AETL's market leadership and innovation focus position it well for long-term value.